CTL Amedica to Enter Asian Market with Interbody Fusion Devices

The Taiwan Food and Drug Administration granted CTL Amedica a license for the silicon nitride-based spinal platform of the Valeo II Lumbar Interbody Fusion Device, Valeo C+CSC Cervical Interbody Fusion Device and the Valeo II Cervical Interbody Fusion Device.

The product line is projected to launch in late 2020 in the region through distributor partner Watson Biomedical Technology.

“We began laying the groundwork for entrance into this important, thriving market upon participating in the 14th Annual Meeting of the Taiwan Neurosurgical Society in 2019, and we are pleased to see these efforts coming to fruition,” said Daniel Chon, CTL Amedica Corporation President and CEO. “The Valeo product line features our proprietary silicon nitride spine technology – the ideal biomaterial for fusion.”